Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27918171 | 0.88 | MAPT (0.69) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL5543934 | 0.86 | MAPT (0.68) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL11299182 | 0.85 | MAPT (0.51) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL5237104 | 0.85 | ADAMTS5 (0.52) | MAPTSMN1; SMN2HTTMAPK1TP53 | |
| SCHEMBL626652 | 0.85 | HTR1A (0.67) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL18711281 | 0.85 | MAPT (0.70) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL18375965 | 0.83 | RAB9A (0.79) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL13688215 | 0.83 | MAPT (0.52) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL29151160 | 0.83 | MAPT (0.52) | MAPTSMN1; SMN2HTTMAPK1RAB9A | |
| SCHEMBL30817600 | 0.83 | MAPT (0.52) | MAPTSMN1; SMN2HTTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | claimed |
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | MAPT 2459/4885SMN1; SMN2 3452/4885HTT 4475/4885 |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | MAPT 593/4885SMN1; SMN2 4550/4885HTT 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.